aTyr Pharma, Inc. (ATYR NASDAQ) stock market data APIs
$5.2574
0.09(1.7%)
as of July 3, 2025
Try our APIs with
free plan!
aTyr Pharma, Inc. Financial Data Overview
Price chart is built with
Anychart
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Prev. Close
5.2574
Open
5.3434
High
5.3434
Low
5.0071
52 wk Range
1.48-5.98
Market Cap
457 M
Shares Outstanding
89 004 K
EPS
-0.17
Beta
0.874
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get aTyr Pharma, Inc. data using free add-ons & libraries
Get aTyr Pharma, Inc. Fundamental Data
aTyr Pharma, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -66 354 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.19
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
aTyr Pharma, Inc. News
New
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of fi...
ATyr Pharma Reports Positive Interim Results From Phase 2 Study Of Efzofitimod In SSc-ILD Patients
(RTTNews) - aTyr Pharma, Inc. (ATYR) announced encouraging interim data from its ongoing Phase 2 EFZO-CONNECT trial, evaluating efzofitimod in patients with systemic sclerosis-related interstitial lun...
High Growth Tech Stocks in the US to Watch This May 2025
The U.S. stock market has experienced significant volatility recently, with major indices like the Dow Jones and Nasdaq Composite seeing sharp gains following a tech sector rally driven by shifts in t...
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. aTyr Pharma, Inc. (NASDAQ:ATYR) was one of the stocks that was covered in that article. Wall Street analysts believ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
